ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,213,763 | -3.3% | 58,242 | +11.2% | 0.00% | 0.0% |
| Q2 2023 | $1,254,799 | +42.8% | 52,392 | +12.2% | 0.00% | 0.0% |
| Q1 2023 | $878,602 | +46.9% | 46,684 | +24.3% | 0.00% | 0.0% |
| Q4 2022 | $597,915 | -3.1% | 37,557 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $617,000 | +13.2% | 37,715 | -2.4% | 0.00% | 0.0% |
| Q2 2022 | $545,000 | -42.8% | 38,655 | -1.7% | 0.00% | 0.0% |
| Q1 2022 | $953,000 | +7.4% | 39,343 | +3.6% | 0.00% | 0.0% |
| Q4 2021 | $887,000 | +3.4% | 37,991 | -26.5% | 0.00% | 0.0% |
| Q3 2021 | $858,000 | -25.3% | 51,668 | +9.8% | 0.00% | 0.0% |
| Q2 2021 | $1,148,000 | +11.3% | 47,058 | +17.7% | 0.00% | 0.0% |
| Q1 2021 | $1,031,000 | -53.4% | 39,965 | -3.5% | 0.00% | -66.7% |
| Q4 2020 | $2,213,000 | +44.1% | 41,401 | +11.2% | 0.00% | +50.0% |
| Q3 2020 | $1,536,000 | -13.9% | 37,234 | +1.1% | 0.00% | -33.3% |
| Q2 2020 | $1,784,000 | +17.0% | 36,816 | +2.0% | 0.00% | 0.0% |
| Q1 2020 | $1,525,000 | -37.0% | 36,103 | -36.2% | 0.00% | -25.0% |
| Q4 2019 | $2,420,000 | +26.3% | 56,567 | +6.3% | 0.00% | 0.0% |
| Q3 2019 | $1,916,000 | -42.0% | 53,236 | -56.9% | 0.00% | -42.9% |
| Q2 2019 | $3,303,000 | +3.4% | 123,580 | +3.9% | 0.01% | 0.0% |
| Q1 2019 | $3,195,000 | +63.2% | 118,995 | -1.7% | 0.01% | +40.0% |
| Q4 2018 | $1,958,000 | -27.9% | 121,105 | -7.4% | 0.01% | -28.6% |
| Q3 2018 | $2,715,000 | +26.3% | 130,768 | -7.1% | 0.01% | +16.7% |
| Q2 2018 | $2,149,000 | -36.2% | 140,754 | -6.1% | 0.01% | -33.3% |
| Q1 2018 | $3,368,000 | -29.5% | 149,904 | -5.5% | 0.01% | -40.0% |
| Q4 2017 | $4,778,000 | +36.2% | 158,672 | +70.3% | 0.02% | +25.0% |
| Q3 2017 | $3,509,000 | +36.8% | 93,155 | +1.3% | 0.01% | +20.0% |
| Q2 2017 | $2,565,000 | +276.1% | 91,955 | +287.9% | 0.01% | +100.0% |
| Q4 2016 | $682,000 | +12.2% | 23,705 | +16.5% | 0.01% | +150.0% |
| Q1 2016 | $608,000 | +26.1% | 20,346 | +45.4% | 0.00% | +100.0% |
| Q4 2015 | $482,000 | +110.5% | 13,996 | +110.2% | 0.00% | 0.0% |
| Q3 2015 | $229,000 | – | 6,657 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |